CRVS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Corvus Pharmaceuticals Inc

NASDAQ | CRVS

9.08

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$677.37M

Market Cap

-

P/E Ratio

-0.54

EPS

$9.55

52 Week High

$2.54

52 Week Low

HEALTHCARE

Sector

CRVS Chart

Recent Chart
Price Action

CRVS Technicals

Tags:

CRVS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$85K
Total Revenue $0
Cost Of Revenue $85K
Costof Goods And Services Sold $85K
Operating Income -$28M
Selling General And Administrative $8.2M
Research And Development $19M
Operating Expenses $28M
Investment Income Net -
Net Interest Income $1.8M
Interest Income $1.8M
Interest Expense $1.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $85K
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$62M

Revenue & Profitability

Earnings Performance

CRVS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $69M
Total Current Assets $54M
Cash And Cash Equivalents At Carrying Value $8.7M
Cash And Short Term Investments $8.7M
Inventory -
Current Net Receivables $216K
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $13M
Short Term Investments $43M
Other Current Assets $2.2M
Other Non Current Assets -
Total Liabilities $36M
Total Current Liabilities $35M
Current Accounts Payable $2.6M
Deferred Revenue -
Current Debt -
Short Term Debt $185K
Total Non Current Liabilities $937K
Capital Lease Obligations $1.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.1M
Other Current Liabilities $33M
Other Non Current Liabilities -
Total Shareholder Equity $33M
Treasury Stock -
Retained Earnings -$397M
Common Stock $7K
Common Stock Shares Outstanding $61M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$25M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $85K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$27M
Cashflow From Financing $49M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$62M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$85K
Total Revenue $0
Cost Of Revenue $85K
Costof Goods And Services Sold $85K
Operating Income -$28M
Selling General And Administrative $8.2M
Research And Development $19M
Operating Expenses $28M
Investment Income Net -
Net Interest Income $1.8M
Interest Income $1.8M
Interest Expense $1.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $85K
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$62M

CRVS News

CRVS Profile

Corvus Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, dedicated to pioneering immuno-oncology therapies aimed at treating various cancers. With a strong pipeline of proprietary drug candidates, the company focuses on enhancing immune responses and improving patient outcomes through precision medicine strategies. By cultivating strategic partnerships and employing innovative research methodologies, Corvus is positioning itself as a significant contributor to the advancement of cancer therapeutics, thereby establishing a compelling presence in the dynamic oncology sector.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BIYA
+11.34%
$0.28
BYND
+2.00%
$1.04
TWOH
0.00%
$0.00
RUBI
-24.69%
$0.16
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
AFMD
-34.94%
$0.18
INTC
+5.13%
$38.70
APLD
+5.05%
$24.94
CLSK
+13.34%
$15.24
SNAP
+0.23%
$7.62
ADTX
+27.38%
$4.00
INHD
-6.51%
$0.21
MSTR
+2.00%
$175.64
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
NAKA
+7.20%
$0.49
KDLY
+7.20%
$0.49
ASST
+2.65%
$1.16
BMNU
+20.08%
$9.03
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
C
+1.31%
$102.50
CHR
0.00%
$0.04
NEHC
+8.33%
$5.07
SMX
+209.42%
$53.84
PLUG
+1.01%
$2.00
NIO
+0.72%
$5.49
IREN
-0.30%
$48.30
DEFT
+20.86%
$1.68
ONDS
-3.80%
$7.92
MPW
+2.12%
$5.77
WULF
+5.49%
$15.65
WFC
+0.54%
$85.56
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCCS
+0.96%
$7.32
PYPL
+0.99%
$61.83
FL
-0.37%
$24.01
VALE
+0.75%
$12.60
DAL
+3.41%
$64.27
CPRT
-0.79%
$38.75
FI
+0.06%
$60.80
AG
+8.35%
$14.63
VGFC
-1.90%
$0.05
VSA
-6.26%
$0.11
IVP
-9.92%
$0.12
CAN
+5.95%
$0.97
NEM
+5.21%
$90.52
NLY
+1.02%
$22.67
WU
+0.58%
$8.67
CRCA
+19.42%
$4.39
CRCL
+7.47%
$78.07
UAA
+2.66%
$4.62
SVMH
-14.58%
$0.73
AGL
+3.94%
$0.66
SPGC
-8.21%
$0.16
CX
+1.43%
$10.57
TMC
+11.40%
$6.49
SGHC
-6.74%
$10.93
TGI
+0.61%
$26.01
FNGB
+2.90%
$21.28
AMZN
+1.06%
$231.61
ABVE
+4.21%
$2.74
BURU
+5.26%
$0.23
MU
+1.62%
$234.01
FRO
-1.95%
$23.52
SOFI
+1.64%
$28.96
PLTR
+0.53%
$166.65
F
+0.50%
$13.25
CRCG
+15.10%
$2.70
ZI
+0.51%
$9.67
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BIYA
+11.34%
$0.28
BYND
+2.00%
$1.04
TWOH
0.00%
$0.00
RUBI
-24.69%
$0.16
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
AFMD
-34.94%
$0.18
INTC
+5.13%
$38.70
APLD
+5.05%
$24.94
CLSK
+13.34%
$15.24
SNAP
+0.23%
$7.62
ADTX
+27.38%
$4.00
INHD
-6.51%
$0.21
MSTR
+2.00%
$175.64
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
NAKA
+7.20%
$0.49
KDLY
+7.20%
$0.49
ASST
+2.65%
$1.16
BMNU
+20.08%
$9.03
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
C
+1.31%
$102.50
CHR
0.00%
$0.04
NEHC
+8.33%
$5.07
SMX
+209.42%
$53.84
PLUG
+1.01%
$2.00
NIO
+0.72%
$5.49
IREN
-0.30%
$48.30
DEFT
+20.86%
$1.68
ONDS
-3.80%
$7.92
MPW
+2.12%
$5.77
WULF
+5.49%
$15.65
WFC
+0.54%
$85.56
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCCS
+0.96%
$7.32
PYPL
+0.99%
$61.83
FL
-0.37%
$24.01
VALE
+0.75%
$12.60
DAL
+3.41%
$64.27
CPRT
-0.79%
$38.75
FI
+0.06%
$60.80
AG
+8.35%
$14.63
VGFC
-1.90%
$0.05
VSA
-6.26%
$0.11
IVP
-9.92%
$0.12
CAN
+5.95%
$0.97
NEM
+5.21%
$90.52
NLY
+1.02%
$22.67
WU
+0.58%
$8.67
CRCA
+19.42%
$4.39
CRCL
+7.47%
$78.07
UAA
+2.66%
$4.62
SVMH
-14.58%
$0.73
AGL
+3.94%
$0.66
SPGC
-8.21%
$0.16
CX
+1.43%
$10.57
TMC
+11.40%
$6.49
SGHC
-6.74%
$10.93
TGI
+0.61%
$26.01
FNGB
+2.90%
$21.28
AMZN
+1.06%
$231.61
ABVE
+4.21%
$2.74
BURU
+5.26%
$0.23
MU
+1.62%
$234.01
FRO
-1.95%
$23.52
SOFI
+1.64%
$28.96
PLTR
+0.53%
$166.65
F
+0.50%
$13.25
CRCG
+15.10%
$2.70
ZI
+0.51%
$9.67
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.